Cannabis Bioscience Reports No Significant Revenue or Profit in FY 2025; Expects VitaCookies to Boost Future Earnings
Cannabis Bioscience International Holdings Inc. recently released its annual report for the fiscal year ending May 31, 2025. The company, headquartered in Houston, Texas, focuses on educational systems related to medical cannabis in the United States and Latin America, and globally through online platforms. It operates through its divisions: Alpha Research Institute, Pharmacology University, and its CBD Business. The company reported its financial results, stating that its operations include conducting clinical trials, providing cannabis-related education, and selling CBD products. However, there is substantial doubt about the company's ability to continue as a going concern unless adequate capital is secured. The company aims to enhance its revenue and profitability by introducing advanced nanotechnology products, which are expected to improve solubility, stability, targeted delivery, and the overall bioavailability of therapeutic compounds. No specific figures for sales, net income, or earnings per share were provided in the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannabis Bioscience International Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-007174), on September 22, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.